Cook G J, Fogelman I
Department of Nuclear Medicine, Guys, Kings and St Thomas' School of Medicine, Kings College, London, England.
Semin Nucl Med. 2001 Jan;31(1):50-61. doi: 10.1053/snuc.2001.18746.
The role of positron emission tomography (PET) in the evaluation and management of skeletal disorders is increasing. A number of reports are available in both benign and malignant disease with a variety of tracers. The bone agent 18F-fluoride can be used to evaluate bone metastases both qualitatively and, for a number of focal and systemic skeletal disorders, quantitatively. 18-Fluorodeoxyglucose is used as a tumor agent in both primary and metastatic bone and bone marrow malignancies; its use has also been described in the evaluation of infection within the skeleton. A possible role for the use of the hypoxia selective tracer 18F-fluoromisonidazole in skeletal infection also exists. This article summarizes the current role of PET in the skeleton with regard to these tracers and diseases.
正电子发射断层扫描（PET）在骨骼疾病评估和管理中的作用日益增强。关于多种示踪剂在良性和恶性疾病中的报告众多。骨显像剂18F-氟化物可用于定性评估骨转移，对于多种局灶性和全身性骨骼疾病，还可进行定量评估。18-氟脱氧葡萄糖在原发性和转移性骨及骨髓恶性肿瘤中用作肿瘤显像剂；其在骨骼感染评估中的应用也有相关报道。缺氧选择性示踪剂18F-氟米索硝唑在骨骼感染中的应用也可能具有一定作用。本文就这些示踪剂和疾病总结了PET目前在骨骼方面的作用。
